^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HBsAg release inhibitor

    Related drugs:
    29d
    GV1001, hTERT Peptide Fragment, Prevents 5-Fluorouracil-Induced Mucositis by Inhibiting Mitochondrial Damages. (PubMed, Cells)
    GV1001 markedly mitigated these 5-FU-induced mitochondrial defects. Taken together, GV1001 mitigates CIM by most likely preserving mitochondrial integrity and function, supporting its potential as a strategy to prevent cancer chemotherapy-associated mucosal injury in patients.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    5-fluorouracil • LucaVax (tertomotide)
    2ms
    GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. (PubMed, Int J Mol Sci)
    GV1001 administered alone or in combination with cisplatin produced antitumor effects. Collectively, these findings demonstrate that GV1001 functions as a potent immunomodulatory anticancer peptide that downregulates CD47 expression and restores macrophage-mediated tumor clearance, highlighting its potential as a therapeutic strategy for OSCC.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • CD47 (CD47 Molecule)
    |
    cisplatin • LucaVax (tertomotide)
    4ms
    GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Samsung Pharmaceutical Co., Ltd. | Trial completion date: Jun 2028 --> Jul 2031
    Trial completion date
    |
    LucaVax (tertomotide)
    7ms
    A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Suzhou HepaThera Biotech Co., Ltd.
    New P2 trial
    7ms
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Completed, GemVax & Kael | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)
    7ms
    Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (clinicaltrials.gov)
    P1, N=59, Completed, GemVax & Kael | Recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)
    7ms
    Therapeutic effects of telomerase-derived peptide GV1001 in experimental autoimmune encephalomyelitis: Inhibiting neuroinflammation and promoting remyelination. (PubMed, Biochem Pharmacol)
    Co-culture assays confirmed that GV1001 blunts microglial neurotoxicity and facilitates remyelination during inflammation. Collectively, the data indicate that GV1001 modulates microglial activity to attenuate neuroinflammation and foster spinal cord repair, underscoring its promise as a multitarget therapy for inflammatory demyelinating diseases such as multiple sclerosis.
    Journal
    |
    TERT (Telomerase Reverse Transcriptase) • IGF1 (Insulin-like growth factor 1) • PRMT1 (Protein Arginine Methyltransferase 1)
    |
    LucaVax (tertomotide)
    9ms
    A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P1/2, N=86, Active, not recruiting, Suzhou HepaThera Biotech Co., Ltd.
    New P1/2 trial
    9ms
    GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) (clinicaltrials.gov)
    P2, N=199, Completed, GemVax & Kael | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Apr 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)
    11ms
    Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, Shanghai Zhongshan Hospital
    New trial
    1year
    A Study of LP-128 Capsules in Healthy Subjects (clinicaltrials.gov)
    P1, N=104, Active, not recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    over1year
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, GemVax & Kael | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    LucaVax (tertomotide)